Free Trial
NYSE:ANVS

Annovis Bio Q4 2023 Earnings Report

Annovis Bio logo
$1.44 -0.11 (-6.77%)
Closing price 03:58 PM Eastern
Extended Trading
$1.46 +0.02 (+1.38%)
As of 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio EPS Results

Actual EPS
-$1.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Annovis Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annovis Bio Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, April 2, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Annovis Bio's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Annovis Bio Earnings Headlines

Annovis Bio stellt neuen Direktor für Biostatistik
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Annovis Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email.

About Annovis Bio

Annovis Bio (NYSE:ANVS), a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

View Annovis Bio Profile

More Earnings Resources from MarketBeat